Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Enrico Campadelli"'
Autor:
Alberto Bongiovanni, Flavia Foca, Manuela Fantini, Maria Rosachiara Forcignanò, Fabrizio Artioli, Rossana Berardi, Enrico Campadelli, Giuseppe Procopio, Francesco Silvestris, Nada Riva, Lorena Gurrieri, Silvia Angela Debonis, Giandomenico Di Menna, Valentina Fausti, Federica Recine, Roberto Vespignani, Toni Ibrahim
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Bone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-related events (SREs) that reduce quality of life. They have also led to increased social and healthcare costs. At present, data available on B
Externí odkaz:
https://doaj.org/article/693a0fc1e87149f99ffcaa4f3dfc147a
Autor:
Francesco Cognetti, Riccardo Ponzone, Mauro Mansutti, Giovanni Sanna, Matteo Lambertini, Lucia Del Mastro, Gruppo Italiano Mammella investigators, Antonio Durando, Silvia Mura, Fabio Puglisi, Stefano Tamberi, Alberto Ballestrero, Francesca Poggio, Grazia Arpino, Paolo Bruzzi, Giancarlo Bisagni, Ornella Garrone, Enrico Campadelli, Sabino De Placido, Andrea Michelotti, Ylenia Urracci, Claudia Bighin, Stefania Gori, Filippo Montemurro, Laura Amaducci, Carla Barone, Alessandra Fabi, Antonio Frassoldati, G. Moretti
Publikováno v:
The Lancet. Oncology. 22(10)
Summary Background The benefit of extending aromatase inhibitor therapy beyond 5 years in the context of previous aromatase inhibitors remains controversial. We aimed to compare extended therapy with letrozole for 5 years versus the standard duration
Autor:
Flavia Foca, Lorena Gurrieri, Federica Recine, Alberto Bongiovanni, Roberto Vespignani, Nada Riva, Giuseppe Procopio, Manuela Fantini, Maria Rosachiara Forcignanò, Francesco Silvestris, Giandomenico Di Menna, Toni Ibrahim, Rossana Berardi, Silvia Angela Debonis, Fabrizio Artioli, Valentina Fausti, Enrico Campadelli
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Scientific Reports
Scientific Reports
Bone metastases (BM) are still the main cause of morbidity in cancer patients because of skeletal-related events (SREs) that reduce quality of life. They have also led to increased social and healthcare costs. At present, data available on BM are ins
Autor:
Francesco Fabbri, Elisabetta Petracci, Alessio Schirone, Dino Amadori, Daniele Andreis, M. Nicolini, Beatrice Campi, Enrico Campadelli, Lorenzo Gianni, Andrea Rocca, Federico Piacentini, Sara Bravaccini, Alessandro Saba, Elisabetta Pietri, Ilaria Massa, Maria Maddalena Tumedei, Sara Ravaioli, Alessandra Gennari, Caterina Donati, Linda Valmorri
Publikováno v:
The Oncologist
Lessons LearnedThe androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited. This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f63f0b7119920bc02314ff4951f79
https://hdl.handle.net/11368/3039670
https://hdl.handle.net/11368/3039670
Autor:
Laura Mercatali, Chiara Spadazzi, Manuela Fantini, Valentina Fausti, Jessica Menis, Francesco Silvestris, Giandomenico Di Menna, Roberto Vespignani, Toni Ibrahim, Rossana Berardi, R. Forcignanò, Flavia Foca, Silvia Angela Debonis, Federica Recine, Banca Dati Metastasi Ossee Study Team, Nada Riva, Giuseppe Procopio, Alberto Bongiovanni, Fabrizio Artioli, Enrico Campadelli, Lorena Gurrieri
Publikováno v:
Journal of Clinical Oncology. 38:e13072-e13072
e13072 Background: Bone Metastases (BM) are still the main cause of morbidity and morbility in cancer patients because of their complications defined as skeletal-related events (SREs).SREs reduce pts quality of life and are associated with an increas
Autor:
Emanuela Scarpi, Giuseppe Schepisi, Cristian Lolli, Francesca Maines, Michele Aieta, Orazio Caffo, Antonello Veccia, Enrico Campadelli, Francesco Carrozza, Vincenzo Emanuele Chiuri, Emanuela Bianchi, Ugo De Giorgi, Vincenza Conteduca, Francesco Massari, Samanta Salvi, Gaetano Facchini
Publikováno v:
The Prostate. 77(9)
Background: Early changes in PSA have been evaluated in association to treatment outcome. The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those
Autor:
Francesca Maines, Giovanni Vicario, Lucia Fratino, Caterina Messina, Vincenza Conteduca, Umberto Basso, Raffaele Ratta, Monica Giordano, Daniele Alesini, Anna Paola Fraccon, Fable Zustovich, Enzo Galligioni, Orazio Caffo, Maddalena Donini, Francesco Massari, Sveva Macrini, Donatello Gasparro, Francesco Verderame, Ugo De Giorgi, Giovanni Lo Re, Alessandro D'Angelo, Giuseppe Procopio, Enrico Campadelli
Publikováno v:
BJU International. 115:764-771
To assess the safety and efficacy of abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated in a compassionate named patient programme (NPP). We retrospectively reviewed the clinical records of patie
Autor:
Vincenza Conteduca, Salvatore Luca Burgio, Paolo Fabbri, Enrico Campadelli, Francesco Carrozza, Ugo De Giorgi, Cecilia Menna, Britt Rudnas, Elisa Carretta, Marco Montanari, Emanuela Bianchi
Publikováno v:
Clinical genitourinary cancer. 13(1)
BACKGROUND: The aim of this study was to assess early serum prostate-specific antigen (PSA) changes in patients treated with abiraterone and to correlate those changes with clinical outcome. PATIENTS AND METHODS: We retrospectively evaluated 103 pati
Autor:
Ugo De Giorgi, Cristian Lolli, Paola Ermacora, Enrico Campadelli, Francesco Verderame, Caterina Messina, Francesca Maines, Orazio Caffo, Donatello Gasparro, Vittorina Zagonel, Maddalena Donini, Vincenza Conteduca, Francesco Massari, Monica Giordano, Daniele Alesini, Alessandro D'Angelo, Umberto Basso, Giovanni Lo Re, Lucia Fratino, Raffaele Ratta, Giuseppe Procopio, Antonello Veccia
Publikováno v:
Future oncology (London, England). 11(21)
Background: The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone. Materials & methods: All CRPC patients received abiraterone 1000 mg daily plus prednison
Autor:
Francesco Massari, Giuseppe Procopio, Caterina Messina, Giovanni Vicario, Vincenza Conteduca, Umberto Basso, Enzo Galligioni, Raffaele Ratta, Ugo De Giorgi, Francesco Verderame, Enrico Campadelli, Orazio Caffo, Monica Giordano, Daniele Alesini, Lucia Fratino, Francesca Maines, Paola Ermacora, Anna Paola Fraccon, Donatello Gasparro, Maddalena Donini, Vittorina Zagonel, Alessandro D'Angelo, Giovanni Lo Re
Publikováno v:
Clinical genitourinary cancer. 14(1)
Metastatic castration-resistant prostate cancer mainly affects older men, opening issues about the efficacy and safety of therapies in this population. We have demonstrated that abiraterone, a selective androgen biosynthesis inhibitor, is a safe and